Famous Patents
British merchant Peter Durand invented the tin can in 1810.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110288251 | POLYMERISATION INITIATOR The invention relates to novel O-dialkylamino-isoureas and polymerizable compositions comprising these O-dialkylamino-isoureas of compounds of the general formula (I). The invention further relates to the use of O-dialkylamino-isoureas as polymerization initiators, espe... | 11/24/2011 |
| 20110263567 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 ... | 10/27/2011 |
| 20100210524 | NOVEL ESTROGEN RECEPTOR LIGANDS The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7<... | 08/19/2010 |
| 20100130784 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-propan-2-ol compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower... | 05/27/2010 |
| 20100130757 | COMPOSITIONS AND METHODS FOR DETECTING NERVE AGENTS The present invention provides methods and compositions for detecting, identifying and measuring the abundance of chemical nerve agents. Methods and compositions of the present invention are capable of providing selective detection of phosphorous based nerve agents, suc... | 05/27/2010 |
| 20100069423 | Use of Chk2 Kinase Inhibitors for Cancer Treatment Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.... | 03/18/2010 |
| 20100029588 | SUBSTITUTED PHENYLAMIDINES AND THE USE THEREOF AS FUNGICIDES The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a... | 02/04/2010 |
| 20090227572 | TREATMENT OF DIABETIC WOUNDS AND PERIPHERAL NEUROPATHIES The present invention provides methods of enhancing healing of wound associated with diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. In another aspect, the instant invention provide... | 09/10/2009 |
| 20090054629 | Inhibitors of Transthyretin Amyloid Fibril Formation Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.... | 02/26/2009 |
| 20090042957 | Substituted Oxyarenes The invention relates to compounds of the formula (I) in which | 02/12/2009 |
| 20090036501 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-α or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-α or PDE4.... | 02/05/2009 |
| 20080221220 | 2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as “DCBP compounds”), and more particularly to co... | 09/11/2008 |
| 20080033049 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents This invention provides estrogen receptor modulators having the structure: wherein R1 to R6 and R8 are as defined in the specification; or a pharmaceutically acceptable salt thereof. ... | 02/07/2008 |
| 20070208078 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT A compound represented by formula (I): [wherein, for example, X is a hydrogen atom or a halogen atom; R1 is a hydrogen atom; R2 is a hydrogen atom or a C1-4 alkyl group; <... | 09/06/2007 |
| 20070161800 | Preparation of Isoxazolin-3-Ylacylbenzene A process is described for preparing isoxazoles of the formula I where the substituents are as defined below:
| |
| 20070149812 | Process for the preparation of norelgestromin Process for the preparation of Norelgestromin or 17α-hydroxy-13β-ethyl-18,19-dinorpregn-4-ene-20-yn-3-one oxime, also in crystalline form, in particular with an E/Z isomer ratio of between 1.3 and 1.5. ... | 06/28/2007 |
| 20060246377 | Halogenated oxime derivatives and the use thereof as latent acids Compounds of the formula (I) or (II) wherein R1 is C1-C10haloalkylsulfonyl, halobenzenesulfonyl, C2-C10haloalkanoyl, halobenzoyl; R2 is halogen or C1-C10 haloalkyl; Ar1 is phenyl, bi... | 11/02/2006 |
| 20050148590 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RARγ agonist ret... | 07/07/2005 |
| 20050009907 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents This invention provides estrogen receptor modulators having the structure where R1-R5 are as defined in the specification; or a pharmaceutically acceptable salt thereof. ... | 01/13/2005 |
